New AstraZeneca COVID-19 vaccine data further support its use as third dose booster
Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that AstraZeneca COVID-19 vaccine (ChAdOx1-S [Recombinant]), when given as a third dose booster, increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, while a separate analysis of samples from the trial showed increased antibody response to the Omicron variant.
The results were observed among individuals previously vaccinated with either AstraZeneca COVID-19 vaccine or an mRNA vaccine.
A separate Phase IV trial reported in a preprint with The Lancet on SSRN showed that a third dose of AstraZeneca COVID-19 vaccine substantially increased antibody levels following a primary vaccine series with CoronaVac (Sinovac Biotech).1
These data add to the growing body of evidence supporting AstraZeneca COVID-19 vaccine as a third dose booster irrespective of the primary vaccination schedules tested.2,3 The Company is submitting these additional data to health authorities around the world given the urgent need for third dose boosters.
Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “AstraZeneca COVID-19 vaccine has protected hundreds of millions of people from COVID-19 around the world and these data show that it has an important role to play as a third dose booster, including when used after other vaccines. Given the ongoing urgency of the pandemic and AstraZeneca COVID-19 vaccine’s increased immune response to the Omicron variant, we will continue to progress regulatory submissions around the world for its use as a third dose booster.”
Professor Sir Andrew J Pollard, chief investigator and director of the Oxford Vaccine Group at the University of Oxford, said: “These important studies show that a third dose of AstraZeneca COVID-19 vaccine after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19. The Oxford-AstraZeneca vaccine is suitable as an option to enhance immunity in the population for countries considering booster programmes, adding to the protection already demonstrated with the first two doses.”
Barbara Nel, Country President, Africa, AstraZeneca, said: ““The latest AstraZeneca COVID-19 vaccine data show the vaccine, when used as a third dose booster, increases the immune response against all variants of concern, including when used after other vaccines. This is of particular importance considering the spread of the Omicron variant. This is really positive news for Sub-Saharan Africa, where over 70M doses of the AstraZeneca COVID-19 vaccine have been supplied, and where countries are striving to attain their vaccination targets and some are beginning to roll out booster programmes.”
The D7220C00001 safety and immunogenicity trial showed that AstraZeneca COVID-19 vaccine continued to be generally well tolerated. Further analyses from the trial are expected in the first half of 2022.
Previous studies support AstraZeneca COVID-19 vaccine as a third dose booster as part of a homologous or heterologous schedule.2,3 In a sub-analysis from the COV001 and COV002 trials, a third dose of AstraZeneca COVID-19 vaccine given at least six months after a second dose significantly boosted antibody levels and maintained T cell response.2 It also resulted in higher neutralising activity against the Alpha, Beta, and Delta variants, compared with a two-dose regimen.2 The COV-BOOST trial also showed that a third dose booster of AstraZeneca COVID-19 vaccine induced significantly higher immune responses compared with controls against the Delta variant and original strain following a primary vaccine series of AstraZeneca COVID-19 vaccine or Pfizer BioNtech (BNT162b2).3